Cargando…
Protective Actions of Anserine Under Diabetic Conditions
Background/Aims: In rodents, carnosine treatment improves diabetic nephropathy, whereas little is known about the role and function of anserine, the methylated form of carnosine. Methods: Antioxidant activity was measured by oxygen radical absorbance capacity and oxygen stress response in human rena...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164239/ https://www.ncbi.nlm.nih.gov/pubmed/30217069 http://dx.doi.org/10.3390/ijms19092751 |
_version_ | 1783359552181239808 |
---|---|
author | Peters, Verena Calabrese, Vittorio Forsberg, Elisabete Volk, Nadine Fleming, Thomas Baelde, Hans Weigand, Tim Thiel, Christian Trovato, Angela Scuto, Maria Modafferi, Sergio Schmitt, Claus Peter |
author_facet | Peters, Verena Calabrese, Vittorio Forsberg, Elisabete Volk, Nadine Fleming, Thomas Baelde, Hans Weigand, Tim Thiel, Christian Trovato, Angela Scuto, Maria Modafferi, Sergio Schmitt, Claus Peter |
author_sort | Peters, Verena |
collection | PubMed |
description | Background/Aims: In rodents, carnosine treatment improves diabetic nephropathy, whereas little is known about the role and function of anserine, the methylated form of carnosine. Methods: Antioxidant activity was measured by oxygen radical absorbance capacity and oxygen stress response in human renal tubular cells (HK-2) by RT-PCR and Western-Immunoblotting. In wildtype (WT) and diabetic mice (db/db), the effect of short-term anserine treatment on blood glucose, proteinuria and vascular permeability was measured. Results: Anserine has a higher antioxidant capacity compared to carnosine (p < 0.001). In tubular cells (HK-2) stressed with 25 mM glucose or 20–100 µM hydrogen peroxide, anserine but not carnosine, increased intracellular heat shock protein (Hsp70) mRNA and protein levels. In HK-2 cells stressed with glucose, co-incubation with anserine also increased hemeoxygenase (HO-1) protein and reduced total protein carbonylation, but had no effect on cellular sirtuin-1 and thioredoxin protein concentrations. Three intravenous anserine injections every 48 h in 12-week-old db/db mice, improved blood glucose by one fifth, vascular permeability by one third, and halved proteinuria (all p < 0.05). Conclusion: Anserine is a potent antioxidant and activates the intracellular Hsp70/HO-1 defense system under oxidative and glycative stress. Short-term anserine treatment in diabetic mice improves glucose homeostasis and nephropathy. |
format | Online Article Text |
id | pubmed-6164239 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61642392018-10-10 Protective Actions of Anserine Under Diabetic Conditions Peters, Verena Calabrese, Vittorio Forsberg, Elisabete Volk, Nadine Fleming, Thomas Baelde, Hans Weigand, Tim Thiel, Christian Trovato, Angela Scuto, Maria Modafferi, Sergio Schmitt, Claus Peter Int J Mol Sci Article Background/Aims: In rodents, carnosine treatment improves diabetic nephropathy, whereas little is known about the role and function of anserine, the methylated form of carnosine. Methods: Antioxidant activity was measured by oxygen radical absorbance capacity and oxygen stress response in human renal tubular cells (HK-2) by RT-PCR and Western-Immunoblotting. In wildtype (WT) and diabetic mice (db/db), the effect of short-term anserine treatment on blood glucose, proteinuria and vascular permeability was measured. Results: Anserine has a higher antioxidant capacity compared to carnosine (p < 0.001). In tubular cells (HK-2) stressed with 25 mM glucose or 20–100 µM hydrogen peroxide, anserine but not carnosine, increased intracellular heat shock protein (Hsp70) mRNA and protein levels. In HK-2 cells stressed with glucose, co-incubation with anserine also increased hemeoxygenase (HO-1) protein and reduced total protein carbonylation, but had no effect on cellular sirtuin-1 and thioredoxin protein concentrations. Three intravenous anserine injections every 48 h in 12-week-old db/db mice, improved blood glucose by one fifth, vascular permeability by one third, and halved proteinuria (all p < 0.05). Conclusion: Anserine is a potent antioxidant and activates the intracellular Hsp70/HO-1 defense system under oxidative and glycative stress. Short-term anserine treatment in diabetic mice improves glucose homeostasis and nephropathy. MDPI 2018-09-13 /pmc/articles/PMC6164239/ /pubmed/30217069 http://dx.doi.org/10.3390/ijms19092751 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Peters, Verena Calabrese, Vittorio Forsberg, Elisabete Volk, Nadine Fleming, Thomas Baelde, Hans Weigand, Tim Thiel, Christian Trovato, Angela Scuto, Maria Modafferi, Sergio Schmitt, Claus Peter Protective Actions of Anserine Under Diabetic Conditions |
title | Protective Actions of Anserine Under Diabetic Conditions |
title_full | Protective Actions of Anserine Under Diabetic Conditions |
title_fullStr | Protective Actions of Anserine Under Diabetic Conditions |
title_full_unstemmed | Protective Actions of Anserine Under Diabetic Conditions |
title_short | Protective Actions of Anserine Under Diabetic Conditions |
title_sort | protective actions of anserine under diabetic conditions |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164239/ https://www.ncbi.nlm.nih.gov/pubmed/30217069 http://dx.doi.org/10.3390/ijms19092751 |
work_keys_str_mv | AT petersverena protectiveactionsofanserineunderdiabeticconditions AT calabresevittorio protectiveactionsofanserineunderdiabeticconditions AT forsbergelisabete protectiveactionsofanserineunderdiabeticconditions AT volknadine protectiveactionsofanserineunderdiabeticconditions AT flemingthomas protectiveactionsofanserineunderdiabeticconditions AT baeldehans protectiveactionsofanserineunderdiabeticconditions AT weigandtim protectiveactionsofanserineunderdiabeticconditions AT thielchristian protectiveactionsofanserineunderdiabeticconditions AT trovatoangela protectiveactionsofanserineunderdiabeticconditions AT scutomaria protectiveactionsofanserineunderdiabeticconditions AT modafferisergio protectiveactionsofanserineunderdiabeticconditions AT schmittclauspeter protectiveactionsofanserineunderdiabeticconditions |